ConductScience.org, home

Gene · 386653

IL31: interleukin 31

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. IL31: interleukin 31. Genes, record 386653. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/386653

On this page

Gene

Symbol
IL31
HGNC
Name
interleukin 31
HGNC
NCBI Gene ID
386653
NCBI Gene
HGNC ID
HGNC:19372
HGNC
Ensembl
ENSG00000204671
NCBI Gene
Aliases
IL-31
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q6EBC2Interleukin-311640Ensembl, GeneID, HGNC

Source UniProt

Patents188

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
WO 2026193162 A12026-09-174Q6EBC2Espacenet
WO 2026193165 A12026-09-174Q6EBC2Espacenet
US 12565527 B12026-03-031Q6EBC2Espacenet
US 12509510 B22025-12-301Q6EBC2Espacenet
US 12473363 B22025-11-18926Q6EBC2Espacenet
WO 2025226834 A12025-10-301Q6EBC2Espacenet
EP 4641201 A22025-10-2910118Q6EBC2Espacenet
US 12448438 B22025-10-2146Q6EBC2Espacenet
JP 2025147176 A2025-10-067033Q6EBC2Espacenet
JP 2025138636 A2025-09-2546Q6EBC2Espacenet

1 to 10 of 188

See all 188 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants867

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleIL31 papersNewest fiscal year
UL1TR001866Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success72025
P30CA016056Roswell Park Cancer Center Support Grant52025
ZIADE000721Molecular Genetic Studies of Somatosensation52025
P30AR075043University of Michigan Skin Biology and Diseases Resource-based Center42025
P30CA008748Cancer Center Support Grant42025
U19AI057229Understanding Influenza and SARS-CoV-2 vaccine responses, in vivo and in vitro42025
P30AG028716Duke Claude D. Pepper Older Americans Independence Center32025
P30AR069589Penn Skin Biology and Diseases Resource-based Center32025
P30AR075049Northwestern University Skin Biology and Diseases Resource-based Center32025
P30CA047904Cancer Center Support Grant32025

1 to 10 of 867Source NIH's project files

See all 867 nih grants

Papers2,753

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Off-Label Uses of Nemolizumab: A Narrative Review.J Drugs Dermatol202642826149PubTator, text miningPubMed
Analytical standardization and inter-platform harmonization of immunoassay-based biomarkers in atopic dermatitis: Challenges and a roadmap for clinical laboratory implementation.Clin Chim Acta202642805450PubTator, text miningPubMed
Differential Expression of miR-146a, IL-31, and IL-33 in Osteoporosis and their Associations with Disease Severity.Comb Chem High Throughput Screen202642786842PubTator, text miningPubMed
EGR1 coordinates a nuclear IL-33-phosphorylated STAT3 transcriptional complex to promote IL31 expression in TLR1/2-activated keratinocytes.Biochem Biophys Res Commun202642748574PubTator, text miningPubMed
Herbal Extracts and Plant-Derived Bioactives in Atopic Dermatitis: Evidence, Mechanisms, Pediatric Safety, and Translational Priorities.Food Sci Nutr202642732250PubTator, text miningPubMed
Real-world effectiveness of a topical dihydroavenanthramide D formulation for chronic pruritus: A multicenter clinical study with molecular evidence of pruritogenic pathway modulation.Narra J202642724128PubTator, text miningPubMed
Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases.Allergy202642713891PubTator, text miningPubMed
Abrocitinib and dupilumab bridging therapy for bullous pemphigoid with insufficient response to initial corticosteroid therapy: a case report.Front Immunol202642707251PubTator, text miningPubMed
: Interleukin-31 in Atopic Dermatitis and Prurigo Nodularis: Pathophysiology, Neuroimmune Mechanisms, and Clinical Efficacy of Nemolizumab.J Drugs Dermatol202642696343PubTator, text miningPubMed
Randomized controlled study of nemolizumab in patients with chronic kidney disease-associated pruritus: NIKAIA-1.J Am Acad Dermatol202642680109PubTator, text miningPubMed

1 to 10 of 2,753

See all 2,753 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/386653

GET https://conductscience.org/api/genes/v1/386653/patents?page=2